Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
15.26
-0.26 (-1.68%)
Aug 25, 2025, 10:11 AM - Market open

Takeda Pharmaceutical Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 20212017 - 2021
Period Ending
Aug '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2017 - 2021
48,04845,07443,39950,86944,66256,329
Upgrade
Market Cap Growth
17.72%3.86%-14.68%13.90%-20.71%17.61%
Upgrade
Enterprise Value
80,03678,05075,91881,75574,56398,218
Upgrade
Last Close Price
15.5214.8713.3815.3612.8715.79
Upgrade
PE Ratio
25.8462.5445.5721.3323.5716.57
Upgrade
PS Ratio
1.551.471.541.681.521.95
Upgrade
PB Ratio
1.010.970.901.060.951.20
Upgrade
P/FCF Ratio
7.777.8812.148.085.426.92
Upgrade
P/OCF Ratio
6.296.399.166.924.836.16
Upgrade
EV/Sales Ratio
2.582.552.692.702.543.40
Upgrade
EV/EBITDA Ratio
9.479.4810.048.467.6511.04
Upgrade
EV/EBIT Ratio
20.6520.7622.9917.5415.0925.62
Upgrade
EV/FCF Ratio
12.9413.6521.2312.999.0612.07
Upgrade
Debt / Equity Ratio
0.730.730.750.770.850.98
Upgrade
Debt / EBITDA Ratio
3.973.964.573.794.075.16
Upgrade
Debt / FCF Ratio
5.535.9410.105.814.815.64
Upgrade
Asset Turnover
0.300.310.290.300.270.25
Upgrade
Inventory Turnover
1.251.301.301.361.401.34
Upgrade
Quick Ratio
0.480.440.500.490.731.00
Upgrade
Current Ratio
1.161.011.110.971.211.53
Upgrade
Return on Equity (ROE)
1.87%1.52%2.12%5.27%4.24%7.60%
Upgrade
Return on Assets (ROA)
2.31%2.40%2.15%2.85%2.88%2.06%
Upgrade
Return on Capital (ROIC)
2.71%2.84%2.61%3.57%3.62%2.59%
Upgrade
Return on Capital Employed (ROCE)
4.70%4.80%3.90%5.40%5.40%3.80%
Upgrade
Earnings Yield
1.98%1.60%2.20%4.69%4.24%6.04%
Upgrade
FCF Yield
12.87%12.69%8.24%12.37%18.44%14.44%
Upgrade
Dividend Yield
3.55%8.80%9.29%8.81%11.52%10.31%
Upgrade
Payout Ratio
91.86%280.28%199.34%88.14%123.30%75.36%
Upgrade
Buyback Yield / Dilution
-1.18%-1.58%-0.67%0.46%-0.23%-0.47%
Upgrade
Total Shareholder Return
2.32%7.22%8.62%9.28%11.29%9.84%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q